Literature DB >> 24336903

Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.

Jingyu Zhu1, Peichen Pan, Youyong Li, Man Wang, Dan Li, Biyin Cao, Xinliang Mao, Tingjun Hou.   

Abstract

Phosphoinositide 3-kinase (PI3K) is known to be closely related to tumorigenesis and cell proliferation, and controls a variety of cellular processes, including proliferation, growth, apoptosis, migration, metabolism, etc. The PI3K family comprises eight catalytic isoforms, which are subdivided into three classes. Recently, the discovery of inhibitors that block a single isoform of PI3K has continued to attract special attention because they may have higher selectivity for certain tumors and less toxicity for healthy cells. The PI3Kβ and PI3Kδ share fewer studies than α/γ, and therefore, in this work, the combination of molecular dynamics simulations and free energy calculations was employed to explore the binding of three isoform-specific PI3K inhibitors (COM8, IC87114, and GDC-0941) to PI3Kβ or PI3Kδ. The isoform specificities of the studied inhibitors derived from the predicted binding free energies are in good agreement with the experimental data. In addition, the key residues critical for PI3Kβ or PI3Kδ selectivity were highlighted by decomposing the binding free energies into the contributions from individual residues. It was observed that although PI3Kβ and PI3Kδ share the conserved ATP-binding pockets, individual residues do behave differently, particularly the residues critical for PI3Kβ or PI3Kδ selectivity. It can be concluded that the inhibitor specificity between PI3Kβ and PI3Kδ is determined by the additive contributions from multiple residues, not just a single one. This study provides valuable information for understanding the isoform-specific binding mechanisms of PI3K inhibitors, and should be useful for the rational design of novel and selective PI3K inhibitors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24336903     DOI: 10.1039/c3mb70314b

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  5 in total

1.  A multi-conformational virtual screening approach based on machine learning targeting PI3Kγ.

Authors:  Jingyu Zhu; Yingmin Jiang; Lei Jia; Lei Xu; Yanfei Cai; Yun Chen; Nannan Zhu; Huazhong Li; Jian Jin
Journal:  Mol Divers       Date:  2021-06-23       Impact factor: 3.364

Review 2.  Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities.

Authors:  Tan Li; Guanyu Wang
Journal:  Int J Mol Sci       Date:  2014-10-20       Impact factor: 5.923

3.  A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.

Authors:  Jingyu Zhu; Man Wang; Yang Yu; Huixin Qi; Kunkun Han; Juan Tang; Zubin Zhang; Yuanying Zeng; Biyin Cao; Chunhua Qiao; Hongjian Zhang; Tingjun Hou; Xinliang Mao
Journal:  Oncotarget       Date:  2015-01-01

4.  A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo.

Authors:  Juan Tang; Jingyu Zhu; Yang Yu; Zubin Zhang; Guodong Chen; Xiumin Zhou; Chunhua Qiao; Tingjun Hou; Xinliang Mao
Journal:  Oncotarget       Date:  2014-06-15

5.  The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo.

Authors:  Fei Shi; Jinying Zhang; Hongyu Liu; Liangliang Wu; Hongyu Jiang; Qiyan Wu; Tianyi Liu; Meiqing Lou; Hao Wu
Journal:  Oncotarget       Date:  2017-12-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.